L-type calcium channel antagonists and suppression of expression of plasminogen receptors: is the missing link the L-type calcium channel?
Bkaily
Ghassan
G
Jacques
Danielle
D
D017311:Amlodipine / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D020746:Calcium Channels, L-Type / Q000187:drug effects* / Q000378:metabolism; D020013:Calcium Signaling / Q000187:drug effects*; D002454:Cell Differentiation / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D015536:Down-Regulation; D006801:Humans; D008264:Macrophages / Q000187:drug effects* / Q000378:metabolism; D008564:Membrane Potentials; D010958:Plasminogen / Q000378:metabolism*; D011956:Receptors, Cell Surface / Q000187:drug effects* / Q000378:metabolism; D014700:Verapamil / Q000494:pharmacology
D000893:Anti-Inflammatory Agents; C079146:CACNA1C protein, human; C514350:CACNA1C protein, mouse; D002121:Calcium Channel Blockers; D020746:Calcium Channels, L-Type; D011956:Receptors, Cell Surface; D017311:Amlodipine; D010958:Plasminogen; D014700:Verapamil